In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The study enrolled adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal ... when cancer cells stop responding to chemotherapy ...

Although preclinical, clinical and pharmacokinetic data support the use of intraperitoneal therapy in ovarian cancer ... or peritoneal carcinoma who had not undergone previous chemotherapy ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and 3-month PFS gain. With PARP inhibitors, OS was not reached after 5 years, ...

Three biomedical research projects conducted NCSU Wilson College of Textiles researchers demonstrate advances in health care ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...